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tomography, PET; TUG, timed up and go test; Movement Disorders Society Revised 
Unified Parkinson's Disease Rating Scale, MDS-UPDRS; VMAT2, vesicular monoamine 
transporter type 2. 
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Abstract: 
Background: Visual function deficits are more common in imbalance-predominant 
compared to tremor-predominant PD suggesting a pathophysiological role of impaired 
visual functions in axial motor impairments. 
Objective: To investigate the relationship between changes in color discrimination and 
motor impairments in PD while accounting for cognitive or other confounder factors. 
Methods: PD subjects (n=49, age 66.7±8.3 years; Hoehn & Yahr stage 2.6±0.6) 
completed color discrimination assessment using the Farnsworth-Munsell 100 Hue 
Color Vision Test, neuropsychological, motor assessments and 
[11
Results: Bivariate correlation coefficients between color discrimination and motor 
variables were significant only for the Timed up and go (R
C]dihydrotetrabenazine vesicular monoamine transporter type 2 PET imaging. MDS-
UPDRS sub-scores for cardinal motor features were computed. Timed up and go 
mobility and walking tests were assessed in 48 subjects.  
S=0.44, P=0.0018) and the 
MDS-UPDRS axial motor scores (RS=0.38, P=0.0068). Multiple regression confounder 
analysis using the Timed up and go as outcome parameter showed a significant total 
model (F(5,43)= 7.3, P<0.0001) with significant regressor effects for color discrimination 
(standardized β=0.32, t=2.6, P=0.012), global cognitive Z-score (β=-0.33, t=-2.5, 
P=0.018), duration of disease (β=0.26, t=1.8, P=0.038), but not for age or striatal 
dopaminergic binding. The color discrimination test was also a significant independent 
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regressor in the MDS-UPDRS axial motor model (standardized β=0.29, t=2.4, P=0.022; 
total model t(5,43)
Conclusions: Color discrimination errors associate with axial motor features in PD 
independent of cognitive deficits, nigrostriatal dopaminergic denervation, and other 
confounder variables. These findings may reflect shared pathophysiology between color 
discrimination visual impairments and axial motor burden in PD.  
= 6.4, P=0.0002).  
 
 
 
Introduction 
 
Visual function deficits, including color discrimination changes, are common non-
motor features in Parkinson's disease (PD) 1, 2. Visual deficits in PD have been 
explained by retinal nerve fiber layer thinning, retinal dopaminergic denervation, and 
central nervous system pathologies 2-4. Performance on a color discrimination task 
associates with cognitive deterioration in PD, in particular, executive function and 
visuospatial deficits 5. Such cognitive deficits correlate also with postural instability gait 
difficulties (PIGD) motor features in PD 6, 7 through a common posterior visual network 
pathway. Interestingly, Bertrand et al. found that color discrimination errors in PD were 
associated with right (posterior) hemispheric white matter changes 5. As right 
hemispheric connectivity changes, including the posterior visual network, have been 
associated with changes in gait in PD 8, we hypothesized that changes in color 
discrimination may also associate with worse axial motor features in PD.   
The purpose of this study was to investigate the relationship between 
performance on a color discrimination task and cardinal motor impairments of PD while 
controlling for the degree of cognitive impairment and other potential confounder 
variables, such as degree of nigrostriatal dopaminergic deficits, age, and duration of 
motor disease.  
 
Subject and Methods 
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Subjects and clinical test battery 
 
 PD patients, n=49 (M35/F15); mean age 66.7±8.3 (51-84) years old; duration of 
motor disease 6.7±4.6 (0.5-20) years; Hoehn & Yahr (HY) stage 2.6±0.6 (1-5); Montreal 
cognitive assessment (MOCA) score 26.4±2.2 (20-30), underwent color discrimination 
visual testing using the Farnsworth-Munsell 100 Hue Test (FMT) with binocular vision 
and identical room illumination 9.  The patient population consisted of a subset of 
subjects who completed the FMT as part of a larger study on non-motor symptoms in 
PD (ClinicalTrials.gov Identifier NCT01565473). The FMT assesses color discrimination 
and requires that patients place scrambled colored disks with varying order by hue. The 
main outcome parameter of this test was the FMT total error rate, with higher error rates 
reflecting greater color discrimination deficiency. We set no time limit for the FMT 
completion, as recommended for patients with neurological disorders 10. Subjects with 
history of color blindness were excluded. A single patient had a history of benign visual 
hallucinations but no active hallucinations at the time of the study.  Assessment of color 
discrimination was performed by a technician who was not involved in the analysis of 
the study. 
Subjects met the UK PD Society Brain Bank clinical diagnostic criteria 11. Abnormal 
striatal dopaminergic ([11C]DTBZ) PET findings were consistent with the diagnosis of PD 
in all subjects. No subjects had a history of a large artery stroke or other significant 
intracranial disease. Most subjects had moderate severity of disease: one subject in 
modified HY stage 1, 11 in stage 2, 19 in stage 2.5, 15 in stage 3, 2 in stage 4, and 1 in 
stage 5. The median HY stage was 2.5. Although patients in HY stage 4 typically use a 
walking aid we examined them without the aid while providing very close supervision at 
arm length during the gait and balance tests. One subject who was unable to walk 
independently (HY stage 5). 
All but two subjects were treated with dopaminergic agents; 23 subjects were taking a 
combination of dopamine agonist and carbidopa-levodopa medications, 17 were using 
carbidopa-levodopa alone, and 7 were taking a dopamine agonist alone. Mean 
levodopa equivalent dose (LED) was 660±491 mg 12. Subjects on dopaminergic drugs 
underwent the MDS-UPDRS motor examination and gait assessments in the morning 
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after withholding dopaminergic drugs overnight. FMT was performed on usual 
dopaminergic drugs and with best corrected vision. Patients on anti-cholinergic or 
cholinesterase inhibitor drugs were not eligible for the study. Patients with contra-
indication for MR imaging or claustrophobia were also not eligible for the study. 
Motor testing was assessed using the MDS-UPDRS, mean total motor score 
(Part III) was 33.3±13.6 (13-72). Summed sub-scores for the cardinal motor features 
were computed: tremor (MDS-UPDRS items 3.15, 3.16, 3.17), rigidity (item 3.3), 
bradykinesia (items 3.4, 3.5, 3.6, 3.7, 3.8 & 3.14) and postural and mobility domains 
(items 2.12, 2.13, 3.10, 3.11, 3.12 & 3.13). During the same session, a measurement of 
the patient’s 8.5-meter walking time, and timed up and go test (TUG) 13 were also 
performed in all subjects, except for one subject who was unable to walk independently. 
Each subject underwent a detailed cognitive examination following an approach 
previously reported to characterize cognitive impairment in PD 14. These tests included 
measures of verbal memory: California Verbal Learning Test 15; executive/reasoning 
functions: WAIS III Picture Arrangement test 16, and Delis-Kaplan Executive Function 
System Sorting Test 17; attention/psychomotor speed as absolute time on the Stroop 1 
test 18; and visuospatial function: Benton Judgment of Line Orientation test 19. A global 
composite cognitive Z-score was calculated based on normative data. 
 This study was approved by the Institutional Review Boards of the University of 
Michigan and VA Ann Arbor Healthcare System. Written informed consent was obtained 
from all subjects prior to any research procedures. 
 
Imaging techniques 
  
 Subjects underwent brain MRI and [11C]DTBZ vesicular monoamine transporter 
type 2 (VMAT2) PET imaging. [11C]DTBZ PET imaging was performed in the morning 
after withholding dopaminergic medications overnight. MRI was performed on a 3 Tesla 
Philips Achieva system (Philips, Best, The Netherlands) and PET imaging was 
performed in 3D imaging mode with an ECAT Exact HR+ tomograph (Siemens 
Molecular Imaging, Inc., Knoxville, TN) 20. The imaging studies were generally 
completed within 1-2 days of the clinical and neuropsychological testing sessions. 
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[11C]DTBZ was prepared as described previously 21. Dynamic PET scanning was 
performed using an intra-venous bolus/infusion protocol for [11C]DTBZ (15 mCi) in 60 
minutes 22.   
 
Analysis 
 
 All image frames were spatially coregistered within subjects with a rigid-body 
transformation to reduce the effects of subject motion during the imaging session 23. 
Interactive Data Language image analysis software (Harris Geospatial Solutions, 
Broomfield, CO) was used to manually trace volumes of interest (VOI) on MRI images 
to include the caudate nucleus and putamen of each hemisphere. VOIs were bilaterally 
averaged. Total neocortical VOI were defined using semi-automated threshold 
delineation of the cortical gray matter signal on the MRI scan 20. 
 [11C]DTBZ distribution volume ratios (DVR) were estimated using the Logan plot 
graphical analysis method with the striatal time activity curves as the input function and 
the total neocortex as reference tissue (a region low in VMAT2 binding sites), with the 
assumption that the non-displaceable distribution is uniform across the brain at 
equilibrium 22.  
 Bivariate Spearman rank correlation coefficients were computed for the 
relationship between color discrimination errors and the motor and cognitive variables. 
Rank-normalized motor and color discrimination variables were used for multiple 
regression analysis to perform a confounder analysis of main effects, using nigrostriatal 
VMAT2 binding, HY motor disease stage, global cognitive Z-score, age, and duration of 
motor disease as covariates. Analyses were performed using SAS version 9.3 (SAS 
institute, Cary, North Carolina). Holm-Bonferroni correction for multiple testing was 
applied. 
 
Results 
 
Main findings 
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 Table 1 provides a summary of the clinical cognitive, motor, and VMAT2 imaging 
findings.  
 
 Higher FMT error scores associated with higher total MDS-UPDRS motor scores 
(RS=0.39, P=0.006) and lower global cognitive Z-scores (R=-0.30, P=0.037). Spearman 
rank correlation coefficients between color discrimination and the UPDRS cardinal 
domain and mobility sub-scores are listed in Table 2. Findings that remained significant 
after Holm-Bonferroni correction included the 3-meter TUG (RS=0.44, P=0.0018) and 
the MDS-UPDRS axial motor scores (RS
 
=0.38, P=0.0068).  
Multivariate confounder analysis of main effects 
 
 Multiple regression analysis using the rank-normalized TUG as outcome 
parameter showed a significant model (F(5,43)
 
= 7.3, P<0.0001) with significant regressor 
effects for FMT (standardized β=0.32, t=2.6, P=0.012), global cognitive Z-score (β=-
0.33, t=-2.5, P=0.018), duration of disease (β=0.26, t=1.8, P=0.038), but not for age 
(β=0.11, t=0.8, P=0.42) or striatal VMAT2 binding (β=-0.15, t=-1.3, P=0.22).  Figure 1 
shows a scatter plot of FMT error rate and the covariate-adjusted TUG times. 
 Multiple regression analysis using the rank-normalized MDS-UPDRS axial motor 
scores as outcome parameter showed a significant model (t(5,43)
 
= 6.4, P=0.0002) with 
significant regressor effects for FMT error rate (standardized β=0.29, t=2.4, P=0.022), 
age (β=0.33, t=2.5, P=0.018), but not for duration of disease (β=0.24, t=1.9, P=0.07), 
global cognitive Z-score (β=-0.04, t=-0.3, P=0.77) or striatal VMAT2 binding (β=-0.18, 
t=-1.5, P=0.15).  
Post hoc analysis: Effects of dopaminergic medications 
 
 As dopaminergic medications may affect vision we performed a post hoc 
regression analysis entering the LED in the TUG model, which confirmed the significant 
regressor effect for FMT error rate (standardized β=0.32, t=2.6, P=0.013; model 
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F(6,41)=6.1, P=0.0001) independent from LED (β=0.18, t=1.2, p=0.23), and the other 
variables. A post hoc regression analysis entering LED in the MDS-UPDRS axial motor 
model showed similar findings: FMT error rate (standardized β=0.26, t=2.1, P=0.042; 
model F(6,41)
 
=6.2, P=0.0001) independent from LED (β=0.23, t=1.6, p=0.12), and the 
other variables. 
 
 
Discussion 
 
 Our findings show that color discrimination errors associate with worse 
performance on the 3-meter TUG test and with more severe axial motor impairments in 
PD. There were non-significant trends of color discrimination performance with 
bradykinesia scores and straight walking times. There were no significant associations 
between color discrimination scores and rigidity or tremor motor features. Although 
there was a significant correlation between impaired color discrimination and more 
severe cognitive impairment 5, our multivariate analysis showed evidence of a selective 
association between color discrimination errors and axial motor impairments 
independent from the degree of cognitive impairment, nigrostriatal dopaminergic 
denervation or other covariates. These findings may reflect shared pathophysiology 
between color discrimination visual changes and axial motor features in PD.  
We previously reported the lack of significant correlation between Rabin contrast 
sensitivity scores and UPDRS motor scores in PD 24. Therefore, our present findings of 
a significant association between color discrimination errors and axial motor features 
suggest that retinal changes alone may not be the principal drivers of the association 
between color discrimination changes and axial motor features. This inference is also 
supported by recent findings that showed no significant correlation between FMT 
performance and photoreceptor thinning in PD 25.  
Prior work reported strong correlations between FMT error rate and impaired 
performance on the grooved pegboard test, a visuomotor test that correlates well with 
overall motor dysfunction in PD. Visuospatial function deficits have been specifically 
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associated with axial motor impairments in PD 6. Quick visuomotor adjustments are 
critical for safe ambulation to prevent falls and it is plausible that central and/or 
oculomotor mechanisms involved with color discrimination changes may contribute to 
axial motor or mobility dysfunctions in PD 26, 27. It may need to be questioned whether 
the FMT, at least in part, is a visuomotor test requiring visual search functions. The FMT 
requires the use frequent short-range saccadic eye movements or fine oculomotor 
adjustments to allow more precise comparison of the hue of the different color disks that 
are spatially aligned on the test board and need to be reordered. It is possible that 
impairments of speed or accuracy of these fine oculomotor functions or related visual 
search mechanisms in PD may potentially contribute to more FMT errors. The 
exploration of the visual surround may be a common feature between the FMT and 
actual visual scanning of the environment for safe ambulation for patients with PD. 
Interestingly, our study findings showed that color discrimination changes were a more 
robust predictor of longer time to complete the TUG compared to straight hallway 
walking, a task that may require less complex visual exploration of the environment.  
 Visuomotor control changes in PD likely include visual cortical dysfunctions that 
may correlate with motor impairments in PD. We previously showed a relationship 
between asymmetry in finger tapping and visual cortical glucose hypometabolism in PD 
28. Bertrand et al. found that changes in color discrimination in PD were associated with 
right (posterior) hemispheric white matter changes, which may be indicative of 
disruption of visual networks 5, 8.  
 Performance on the FMT may also be affected by the effects of aging 29. 
However, our primary findings were independent from the effect of age. Furthermore, 
the FMT is a cognitively demanding task but our findings were independent from 
cognitive performance scores in our study. 
 This study has limitations, including absence of a systematic ophthalmological or 
retinal assessment. None of our subjects, however, had a history of color blindness, 
diplopia, or known glaucoma, and all subjects had optimal (corrected) visual acuity. Our 
study is cross-sectional nature and no inferences regarding causation can be made. 
Another limitation of the study is the lack of genetic testing for the glucocerebrosidase 
(GBA) gene as patients with PD with GBA mutations have more prominent progression 
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of axial motor and non-motor impairments 30.  
 Color discrimination testing has been shown to be a predictor of PD in patients 
with dream enactment behavior 31. Within the setting of symptomatic PD, color 
discrimination testing may also have the potential value as a screening tool to identify or 
predict more severe patterns of disease progression in PD. The cross-sectional nature 
of our study does not allow evaluation of this hypothesis. A longitudinal study will be 
necessary to determine if color discrimination evaluations could be used to predict the 
transition to more severe motor subtypes of PD. 
 We conclude that color discrimination errors selectively associate with axial 
motor features and mobility functions in PD. Our findings are not explained by a 
cognitive confounder effect or the degree of nigrostriatal degeneration, age, 
dopaminergic medication dose, or duration of disease.  Assessment of visual functions, 
in particular color discrimination, may be important for future mobility studies in PD. 
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Legend 
 
Figure 1: Scatter plot of the distribution of FMT color discrimination error scores and 
TUG times (cov. adj.: adjusted for co-variates of global cognitive Z-score, striatal 
VMAT2 binding, duration of disease, and age). Rank values are ordered from less to 
more severely abnormal scores on the test measures.  Au
th
or
 M
an
us
cr
ip
t
 This article is protected by copyright. All rights reserved 
Table 1.  
 
Summary of color discrimination, cognitive, motor, and VMAT2 imaging findings. 
Abbreviations: dihydrotetrabenazine, DTBZ; FMT, Farnsworth-Munsell 100 Hue 
Color Vision Test; LED, Levodopa equivalent dose; MCI, mild cognitive 
impairment; TUG, timed up and go test; Movement Disorders Society Revised 
Unified Parkinson's Disease Rating Scale, MDS-UPDRS; VMAT2, vesicular 
monoamine transporter type 2. MDS-UPDRS, TUG and gait testing was 
performed in the dopaminergic medication ‘off’ state. 
 
 Mean value (standard 
deviation / range) 
Global cognitive Z-score -0.270.72 (range -2.39-0.98) 
MCI 17/49 (34.7%) 
FMT errors 82.050.1 (range 4-228) 
LED 660.3490.8 (0-2,190) 
Striatal [11C]DTBZ VMAT2 distribution volume ratio 1.960.31 (range 1.38-3.03) 
MDS-UPDRS part III (motor) score 
 
33.713.0 (range 11-72) 
MDS-UPDRS axial motor core 6.04.5 (range 1-24) 
TUG (seconds; n=48) 9.12.8 (range 4.4-18.8) 
8.5 meter walking test (seconds; n=48) 8.22.2 (range 5.1-17.2) 
Table 2. 
 
Spearman rank correlation coefficients between color discrimination and the 
UPDRS cardinal motor domain and timed mobility scores. Findings that remained 
significant after Holm-Bonferroni correction are depicted in bold font. MDS-
UPDRS, Timed Up and Go and gait testing was performed in the dopaminergic 
medication ‘off’ state. 
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 Correlation coefficient with color 
discrimination scores 
MDS-UPDRS domain sub-
scores 
(n=49) 
 
Rigidity RS=0.22 (P=0.13) 
Tremor RS=-0.06 (P=0.68) 
Bradykinesia RS=0.35 (P=0.013) 
Axial RS=0.38 (P=0.0068)* 
Timed mobility scores (n=48)  
3-meter Timed Up and Go  RS=0.44 (P=0.0018)* 
8.5 meter walking test  RS=0.32 (P=0.027) 
* Significant after Holm-Bonferroni correction 
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